Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines

被引:50
作者
Nakamura, S
Otani, T
Okura, R
Ijiri, Y
Motoda, R
Kurimoto, M
Orita, K
机构
[1] Hayashibara Biochem Labs Inc, Fujisaki Cell Ctr, Okayama, Japan
[2] Hayashibara Biochem Labs Inc, Fujisaki Inst, Okayama, Japan
关键词
IL-18; receptor; expression; deglycosilation; KG-1; TNF-alpha;
D O I
10.1038/sj.leu.2401789
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-18 (IL-18) is a new inflammatory cytokine sharing biological functions with IL-12. The human IL-18 receptor (IL-18R) was recently identified and was found to be expressed on normal peripheral blood lymphocytes. To further characterize IL-18R, we analyzed IL-18R expression using a series of human hematopoietic cell lines selected from various cell lineages. We found the IL-18R expression on cells of T and B lineages as expected from analysis on normal cells. The IL-18R expression, however, was found not to be restricted to any specific maturation stages of T and B cells, In addition, we detected IL-18R expression in myeloid, monocytoid, erythroid and megakaryocytic cell lines, indicating that normal counterparts of these cell lineages could express IL-18R and participate in in vivo reactions caused by IL-18, Biochemical studies showed that IL-18R proteins exist as heterogeneous molecules ranging from 60 to 110 kDa. Deglycosilation experiments indicated that the heterogeneity could not be explained only by a difference in glycosilation. We also found that tumor necrosis factor-a (TNF-alpha) modulated the IL-18R expression, which implies an important in vivo effect of TNF-alpha on IL-18-induced reaction. Analyzing the responsiveness of IL-18R, we found that only KG-1 responded to IL-18 stimulation. This suggests that certain inhibitory mechanisms of IL-18 responsive genes are involved in the all IL-18R-positive cell lines except KG-1.
引用
收藏
页码:1052 / 1059
页数:8
相关论文
共 32 条
[1]  
Ahn HJ, 1997, J IMMUNOL, V159, P2125
[2]  
Bohn E, 1998, J IMMUNOL, V160, P299
[3]   Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling [J].
Born, TL ;
Thomassen, E ;
Bird, TA ;
Sims, JE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (45) :29445-29450
[4]   Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Wysocka, M ;
Aruga, E ;
Kurzawa, H ;
Chang, AE ;
Hunter, CA ;
Fox, JC ;
Trinchieri, G ;
Lee, WMF .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1441-1452
[5]  
Dao T, 1998, J IMMUNOL, V161, P2217
[6]  
FISCHER P, 1988, BLOOD, V72, P234
[7]  
Hofstra CL, 1998, J IMMUNOL, V161, P5054
[8]  
Hoshino K, 1999, J IMMUNOL, V162, P5041
[9]  
Kawakami K, 1997, J IMMUNOL, V159, P5528
[10]  
Kohno K, 1997, J IMMUNOL, V158, P1541